High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis.

نویسندگان

  • Mohammad Hassan Bemanian
  • Masoud Movahedi
  • Abolhassan Farhoudi
  • Mohammad Gharagozlou
  • Mehran Heidari Seraj
  • Zahra Pourpak
  • Mohammad Nabavi
  • Asghar Aghamohammadi
  • Zahra Shirkhoda
چکیده

Atopic dermatitis is one of the most common allergic diseases that almost always respond to conventional therapies with topical emollient, topical corticosteroids, systemic antihistamines and allergic abstinence. However few cases of atopic dermatitis with severe course do not respond to conventional therapies and high dose of intravenous immunoglobulin or cyclosporine are recommended for them. This clinical trial study has been done to compare the last two regimens in patients with severe atopic dermatitis, Scoring Atopic Dermatitis (SCORAD) greater than 70. We included 14 patients in two groups. In group 1, eight patients were randomly selected and received 4mg/kg cyclosporine daily for 3 months and in group 2, six patients received 2g/kg Intravenous Immunoglobulin (IVIG) as stat infusion. All patients were followed on days 15, 30, 60 and 90 after starting the therapy. About 75% and 62.5% of patients had positive skin tests to egg and to milk respectively. Six patients out of 14 patients did not have skin test, so specific IgE by Radioallergosobent tests (RAST) was used for them. All of these patients had positive RAST to egg and 66.6% against cow's milk. There was a significant difference in the clinical outcomes of these two groups with a marked reduction in SCORAD of day 90th in group 1 in comparison to group 2 (P-value = 0.005). No significant adverse drug reaction was seen in these two groups.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Oral Selenium in the treatment of refractory severe Atopic dermatitis: Report of 4 cases

Atopic dermatitis (AD) is a chronic, inflammatory and pruritic skin disease with a prevalence of 10-20%. Recent studies suggested the effect of selenium on immunoregulation in AD. In this study we report 4 cases of atopic dermatitis according to Hafniin and Rajka criteria. Serum selenium levels were increased and serum total IgE were decreased in all patients. These results show that selenium i...

متن کامل

گزارش درمان شش مورد کولیت اولسروز مقاوم به درمان استاندارد با سیکلوسپرین

Background and purpose: Treatment of refractory ulcerative colitis (ÜÇ) is a problem in the intestinal tract diseases. Different researches have shown that intravenous administration of cyclosporine before surgical operation can be effective. But less is known about the oral administration of cyclosporine given at the onset of the treatment of refractory ÜÇ. Ïn this study effectiveness and si...

متن کامل

Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report

The management of severe recalcitrant atopic dermatitis (AD) is a challenging issue for clinicians and patients. We hypothesized that repeated intramuscular injections of autologous immunoglobulin (autologous immunoglobulin therapy: AIGT) might induce clinical improvements in patients with AD by stimulation of the active immune response to antigen-binding-site of pathogenic antibodies. We tried...

متن کامل

Transient hypogammaglobulinemia and severe atopic dermatitis: Open-label treatment with immunoglobulin in a case series

BACKGROUND We reported on six infants between 5 and 11 months old, with transient hypogammaglobulinemia of infancy and severe refractory atopic dermatitis, who were treated with open-label immunoglobulin (Ig) after conventional therapy failed. All six infants had an IgG level of <225 mg/dL, elevated eosinophil and IgE levels, and no urine or stool protein losses, but they did exhibit hypoalbumi...

متن کامل

Update on systemic therapies for atopic dermatitis.

PURPOSE OF REVIEW Although many atopic dermatitis patients can be treated satisfactorily with topical medications and systemic anti-itch approaches, a smaller subset require more aggressive systemic therapies. Familiarity with the latest literature on the benefits and risks of these treatments will enable the clinician and patient to select the most appropriate therapy based on the patient's li...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Iranian journal of allergy, asthma, and immunology

دوره 4 3  شماره 

صفحات  -

تاریخ انتشار 2005